Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Signs up Turkish Distributor for Cancer Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics said today that it has signed up the biomedical distributor Dateks to market its colorectal cancer test in Turkey.

Epigenomics said that Dateks will market the Epi proColon, a DNA methylation-based test that detects colorectal cancer in blood plasma by identifying the Septin 9 biomarker.

Even though Cancer Early Diagnosis and Screening Centers have been set up in most provinces and the Turkish Ministry of Health has implemented CRC screening standards, screening is still low, Epigenomics said. The company said that this has "severe consequences as colorectal cancer is highly curable when detected at an early [and] still localized stage."

Dateks CEO Süha Dere said in a statement that this blood test is "as simple clean solution" that "can be performed at any time and it does not require any preparation of the screened individual."
"We believe this test can help significantly to drive acceptance of colorectal cancer early detection in the Turkish population," Dere added.

Epigenomics currently markets the Epi proColon test directly in Germany, Austria, and Switzerland.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.